Strain-Specific Properties and T Cells Regulate the Susceptibility to Papilloma Induction by Papillomavirus 1

English version České info

Infection with papillomaviruses can cause benign warts (papillomas) on skin and mucosae of humans and animals but also malignancies, especially anogenital carcinomas and, in genetically predisposed or immunocompromised individuals, cutaneous squamous cell cancers. Control and clearance of these viruses are thought to be mediated by the cellular immune system, however experimental determination for the necessary cellular effector(s) is lacking. The recently identified mouse papillomavirus (MusPV1, also designated “MmuPV1”) is known to induce papilloma formation on skin of immunodeficient mice. However, its pathogenesis in immunocompetent mice is unclear. Our study shows that in an immunocompetent setting, MusPV1 generally causes asymptomatic skin infections, but no lesion outgrowth. Visible papillomas were consistently observed after profound immunosuppression in some, but not other, strains of mice. By selective removal of distinct cellular immune populations and employing genetically modified mice, we could show that T cells are pivotal for controlling MusPV1 infection and disease. We further show that surprising differences in the T cell subsets are required for protection in different strains of immunocompetent mice. This implies that unanticipated effector mechanisms can control virus infection and pathogenesis in specific genetic backgrounds. The findings may help to explain the wide of range of pathologic outcomes of infection by a specific human papillomavirus type in immunocompetent people.

Vyšlo v časopise: Strain-Specific Properties and T Cells Regulate the Susceptibility to Papilloma Induction by Papillomavirus 1. PLoS Pathog 10(8): e32767. doi:10.1371/journal.ppat.1004314
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1004314

Souhrn

Zdroje

1. Howley PM, Schiller JT, Lowy DR (2013) Papillomaviruses. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins. pp. 1662–1703.

2. ParsonsRJ, KiddJG (1942) Oral Papillomatosis of Rabbits: a Virus Disease. J Exp Med 77: 233–250.

3. NindlI, GottschlingM, StockflethE (2007) Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 23: 247–259.

4. MorisonWL (1975) Viral warts, herpes simplex and herpes zoster in patients with secondary immune deficiencies and neoplasms. Br J Dermatol 92: 625–630.

5. CampoMS (2003) Papillomavirus and disease in humans and animals. Vet Comp Oncol 1: 3–14.

6. IngleA, GhimS, JohJ, ChepkoechI, Bennett JensonA, et al. (2011) Novel laboratory mouse papillomavirus (MusPV1) infection. Vet Pathol 48: 500–505.

7. JohJ, JensonAB, ProctorM, IngleA, SilvaKA, et al. (2012) Molecular diagnosis of a laboratory mouse papillomavirus (MusPV1). Exp Mol Pathol 93: 416–421.

8. CladelNM, BudgeonLR, CooperTK, BaloghKK, HuJ, et al. (2013) Secondary infections, expanded tissue tropism and evidence for malignant potential in immunocompromised mice infected with Mus musculus papillomavirus 1 (MmuPV1) DNA and virus. J Virol 87: 9391–9395.

9. HandisuryaA, DayPM, ThompsonCD, BuckCB, PangY-YS, et al. (2013) Characterization of Mus musculus Papillomavirus 1 (MusPV1) Infection In Situ Reveals an Unusual Pattern of Late Gene Expression and Capsid Protein Localization. J Virol 87: 13214–13225.

10. AbelEL, AngelJM, KiguchiK, DiGiovanniJ (2009) Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc 4: 1350–1362.

11. HenningsH, DevorD, WenkML, SlagaTJ, FormerB, et al. (1981) Comparison of two-stage epidermal carcinogenesis initiated by 7,12-dimethylbenz(a)anthracene or N-methyl-N′-nitro-N-nitrosoguanidine in newborn and adult SENCAR and BALB/c mice. Cancer Res 41: 773–779.

12. HenningsH, GlickAB, LowryDT, KrsmanovicLS, SlyLM, et al. (1993) FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin. Carcinogenesis 14: 2353–2358.

13. HandisuryaA, DayPM, ThompsonCD, BuckCB, KwakK, et al. (2012) Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species. Virology 433: 385–394.

14. HamawyMM (2003) Molecular actions of calcineurin inhibitors. Drug News Perspect 16: 277–282.

15. HolländerGA, BiererBE, BurakoffSJ (1994) Molecular and biological actions of cyclosporin A and FK506 on T cell development and function. Transfus Sci 15: 207–220.

16. MaglennonGA, McIntoshP, DoorbarJ (2011) Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 414: 153–163.

17. MaglennonGA, McIntoshPB, DoorbarJ (2014) Immunosuppression facilitates the reactivation of latent papillomavirus infections. J Virol 88: 710–716.

18. WhiteWI, WilsonSD, BonnezW, RoseRC, KoenigS, et al. (1998) In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 72: 959–964.

19. OzbunMA (2002) Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription. J Virol 76: 11291–11300.

20. Van der BurgSH, PalefskyJM (2009) Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful. J Transl Med 7: 108 doi: 10.1186/1479-5876-7-108

21. ColemanN, BirleyHD, RentonAM, HannaNF, RyaitBK, et al. (1994) Immunological events in regressing genital warts. Am J Clin Pathol 102: 768–774.

22. TrimbleCL, ClarkRA, ThoburnC, HansonNC, TassellomJ, et al. (2010) Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 185: 7107–7114.

23. WooYL, SterlingJ, DamayI, ColemanN, CrawfordR, et al. (2008) Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG 115: 1616–1622.

24. KnowlesG, O'NeilBW, CampoMS (1996) Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J Virol 70: 8451–8458.

25. NichollsPK, MoorePF, AndersonDM, MooreRA, ParryNR, et al. (2001) Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 283: 31–39.

26. WilgenburgBJ, BudgeonLR, LangCM, GriffithJW, ChristensenND (2005) Characterization of immune responses during regression of rabbit oral papillomavirus infections. Comp Med 55: 431–439.

27. SelvakumarR, SchmittA, IftnerT, AhmedR, WettsteinFO (1997) Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression. J Virol 71: 5540–5548.

28. WilliamsMA, BevanMJ (2007) Effector and memory CTL differentiation. Annu Rev Immunol 25: 171–192.

29. WherryEJ, AhmedR (2004) Memory CD8 T-cell differentiation during viral infection. J Virol 78: 5535–5545.

30. WhitmireJK (2011) Induction and function of virus-specific CD4+ T cell responses. Virology 411: 216–228.

31. BullerRM, HolmesKL, HüginA, FredericksonTN, MorseHC3rd (1987) Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature 328: 77–79.

32. RuedlC, KopfM, BachmannMF (1999) CD8(+) T cells mediate CD40-independent maturation of dendritic cells in vivo. J Exp Med 189: 1875–1884.

33. YauchLE, PrestwoodTR, MayMM, MorarMM, ZellwegerRM, et al. (2010) CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 185: 5405–5416.

34. HamiltonSE, TvinnereimAR, HartyJT (2001) Listeria monocytogenes infection overcomes the requirement for CD40 ligand in exogenous antigen presentation to CD8(+) T cells. J Immunol 167: 5603–5609.

35. NakanishiY, LuB, GerardC, IwasakiA (2009) CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462: 510–513.

36. BennettSR, CarboneFR, KaramalisF, FlavellRA, MillerJF, et al. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478–480.

37. HernandezMG, ShenL, RockKL (2007) CD40-CD40 ligand interaction between dendritic cells and CD8T cells is needed to stimulate maximal T cell responses in the absence of CD4 T cell help. J Immunol 178: 2844–2852.

38. JohnsonS, ZhanY, SutherlandRM, MountAM, BedouiS, et al. (2009) Selected Toll-like receptor ligands and viruses promote helper-independent cytotoxic T cell priming by upregulating CD40L on dendritic cells. Immunity 30: 218–227.

39. CombeCL, CurielTJ, MorettoMM, KhanIA (2005) NK cells help to induce CD8(+)-T-cell immunity against Toxoplasma gondii in the absence of CD4(+) T cells. Infect Immun 73: 4913–4921.

40. SwainSL, McKinstryKK, StruttTM (2012) Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol 12: 136–148.

41. SoghoianDZ, StreeckH (2010) Cytolytic CD4(+) T cells in viral immunity. Expert Rev Vaccines 9: 1453–1463.

42. SantAJ, McMichaelA (2012) Revealing the role of CD4(+) T cells in viral immunity. J Exp Med 209: 1391–1395.

43. JellisonER, KimSK, WelshRM (2005) Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 174: 614–618.

44. GaspariAA, JenkinsMK, KatzSI (1988) Class II MHC-bearing keratinocytes induce antigen-specific unresponsiveness in hapten-specific Th1 clones. J Immunol 141: 2216–2220.

45. YusufN, NastiTH, KatiyarSK, JacobsMK, SeibertMD, et al. (2008) Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res 68: 3924–3930.

46. RobertsSJ, NgBY, FillerRB, LewisJ, GlusacEJ, et al. (2007) Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A 104: 6770–6775.

47. BoxmanIL, BerkhoutRJ, MulderLH, WolkersMC, Bouwes BavinckJN, et al. (1997) Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 108: 712–715.

48. AntonssonA, ErfurtC, HazardK, HolmgrenV, SimonM, et al. (2003) Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. J Gen Virol 84: 1881–1886.

49. MeyerT, ArndtR, NindlI, UlrichC, ChristophersE, et al. (2003) Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients. Transpl Int 16: 146–153.

50. HarwoodCA, SurentheranT, McGregorJM, SpinkPJ, LeighIM, et al. (2000) Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 61: 289–297.

51. WeissenbornS, NealeRE, WaterboerT, AbeniD, BavinckJN, et al. (2012) Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients. Med Microbiol Immunol 201: 117–25.

52. BuckCB, ThompsonCD (2007) Production of papillomavirus-based gene transfer vectors. Curr Protoc Cell Biol 37: 26.1.1–26.1.19.

53. BlümlS, BonelliM, NiederreiterB, PuchnerA, MayrG, et al. (2011) Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum 63: 1281–1288.